within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB12_ElosulfaseAlfa;

model ElosulfaseAlfa
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 4.722222222222222e-07,
    adminDuration = 600,
    adminMass = 2 / 1000000,
    adminCount = 1,
    Vd = 0.0037,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0013,
    k12 = 8.88888888888889e-07,
    k21 = 8.88888888888889e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>ElosulfaseAlfa</td></tr><tr><td>ATC code:</td><td>A16AB12</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>2</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.7</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Elosulfase alfa is a recombinant form of human N-acetylgalactosamine 6-sulfatase (GALNS), indicated for the treatment of mucopolysaccharidosis IVA (MPS IVA, also known as Morquio A syndrome). It is an enzyme replacement therapy approved for use in patients with this rare, inherited, lysosomal storage disorder.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in pediatric and adult patients with MPS IVA following intravenous infusion of elosulfase alfa at 2 mg/kg once weekly over approximately 4 hours.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A16AB12 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end ElosulfaseAlfa;
